Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2606 - Prognostic value of pre-operative neutrophil-to-lymphocyte ratio in patients with glioblastoma multiforme


10 Sep 2017


Poster display session


Central Nervous System Malignancies


Yasemin Kemal


Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366


Y. Kemal1, O. Oltulu1, E. Odabasi2, O. Ozdemir3, I. Yucel4

Author affiliations

  • 1 Medical Oncology, Samsun Training and Research Hospital, 55200 - Samsun/TR
  • 2 Radiation Oncology, Samsun Training and Research Hospital, 55200 - Samsun/TR
  • 3 Radiation Oncology, Samsun Training and Research Hospital, 55200 - Samsun/TR
  • 4 Department Of Medical Oncology, 19 Mayis University Hospital,, 55200 - Samsun/TR


Abstract 2606


Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour. GBM development is is closely associated with inflammation status and immune response. The neutrophil-to-lymphocyte ratio (NLR) is a marker of host immune response and its elevation has recently been shown to be a poor prognostic factor in many malignancies including colon, prostate, lung, and bladder cancer. We aimed to investigate the prognostic value of preoperative NLR in GBM patients.


Between 2010 and 2016; 104 patients had surgery for GBM and were assessed for consideration of adjuvant therapy at our institution. Of these, 80 patients with an evaluable pre-corticosteroid full blood count result were identified and included in the final analysis.


The mean tumor diameter was 41mm, most of them were found in the right hemisphere (56%) and in the temporal lobe (27.5%). 85% of the patients received adjuvant chemoradiotherapy (with temozolamide). Median overall survival was 13.4 moths. Patients with NLR 4. But this difference was not statistically significant (p > 0.05).


Our results suggest that pretreatment NLR could be a useful marker for predicting prognosis in GBM patients but large scale trials are needed to confirm this.

Clinical trial identification

Legal entity responsible for the study

Ozlem Oltulu




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.